Price T Rowe Associates Inc. MD Sells 151,611 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Price T Rowe Associates Inc. MD lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 12.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,104,037 shares of the medical equipment provider's stock after selling 151,611 shares during the quarter. Price T Rowe Associates Inc. MD owned 1.59% of Lantheus worth $98,769,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. World Investment Advisors LLC bought a new position in Lantheus in the third quarter valued at about $60,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Lantheus during the 3rd quarter valued at approximately $25,000. Tidal Investments LLC lifted its stake in Lantheus by 25.2% in the 3rd quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider's stock valued at $1,934,000 after purchasing an additional 3,547 shares during the last quarter. GAMMA Investing LLC boosted its position in Lantheus by 118.0% in the fourth quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider's stock valued at $91,000 after buying an additional 551 shares in the last quarter. Finally, Everence Capital Management Inc. bought a new stake in shares of Lantheus during the fourth quarter worth $210,000. Institutional investors own 99.06% of the company's stock.

Lantheus Stock Performance

Shares of LNTH stock traded up $1.58 during trading hours on Thursday, hitting $105.92. 979,689 shares of the company were exchanged, compared to its average volume of 951,309. Lantheus Holdings, Inc. has a fifty-two week low of $65.89 and a fifty-two week high of $126.89. The company has a 50 day simple moving average of $98.78 and a two-hundred day simple moving average of $95.20. The firm has a market cap of $7.25 billion, a P/E ratio of 17.62 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on LNTH shares. JMP Securities reissued a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial raised their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, B. Riley decreased their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.